"SEATTLE — Nov. 24, 2010 —A decade of refinements in marrow and stem cell transplantation to treat blood cancers significantly reduced
the risk of treatment-related complications and death, according to an institutional self-analysis of transplant-patient outcomes conducted
at Fred Hutchinson Cancer Research Center.
Among the major findings of the study, which compared transplant-patient outcomes in the mid-‘90s with those a decade later:
After adjusting for factors known to be associated with outcome, the researchers observed a statistically significant 60 percent reduction
in the risk of death within 200 days of transplant and a 41 percent reduction in the risk of overall mortality at any time after transplant.
“Everything we looked at improved a decade after the initial analysis,” said George McDonald, M.D., a Hutchinson Center gastroenterologist
and corresponding author of the paper, which was published Nov. 25, 2010 in the New England Journal of Medicine
Read Full FHCRC Press Release »
Read NEJM Editorial »
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
Ted A. Gooley, Ph.D., Jason W. Chien, M.D., Steven A. Pergam, M.D., M.P.H., Sangeeta Hingorani, M.D., M.P.H., Mohamed L. Sorror, M.D.,
Michael Boeckh, M.D., Paul J. Martin, M.D., Brenda M. Sandmaier, M.D., Kieren A. Marr, M.D., Frederick R. Appelbaum, M.D., Rainer Storb, M.D.,
and George B. McDonald, M.D. N Engl J Med 2010; 363:2091-2101.
Read NEJM Article »